The estimated Net Worth of Samuel Wu is at least $566 mil dollars as of 1 April 2014. Samuel Wu owns over 75,735 units of Applied Genetic Technologies Corp stock worth over $566,356 and over the last 11 years Samuel sold AGTC stock worth over $0.
Samuel has made over 1 trades of the Applied Genetic Technologies Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Samuel bought 75,735 units of AGTC stock worth $908,820 on 1 April 2014.
The largest trade Samuel's ever made was buying 75,735 units of Applied Genetic Technologies Corp stock on 1 April 2014 worth over $908,820. On average, Samuel trades about 75,735 units every 0 days since 2014. As of 1 April 2014 Samuel still owns at least 1,452,196 units of Applied Genetic Technologies Corp stock.
You can see the complete history of Samuel Wu stock trades at the bottom of the page.
Samuel's mailing address filed with the SEC is C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA, FL, 32615.
Over the last 11 years, insiders at Applied Genetic Technologies Corp have traded over $12,578,298 worth of Applied Genetic Technologies Corp stock and bought 760,946 units worth $8,946,827 . The most active insiders traders include Plc Gsk, Edward Hurwitz, eVentures, Inc. Med Immune. On average, Applied Genetic Technologies Corp executives and independent directors trade stock every 89 days with the average trade being worth of $18,318. The most recent stock trade was executed by Stephen W Potter on 30 June 2022, trading 8,070 units of AGTC stock currently worth $6,214.
Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.
Applied Genetic Technologies Corp executives and other stock owners filed with the SEC include: